Galectin Therapeutics (GALT) Debt Ratio (2024 - 2025)
Galectin Therapeutics' quarterly Debt Ratio came in at 0.29 in Q3 2025, up 2247.35% year-on-year from 0.01 in Q3 2024, and up 808.65% quarter-over-quarter from 0.03 in Q1 2025.
Galectin Therapeutics has reported Debt Ratio for 2 years, with the latest figure at 0.29 in Q3 2025.
- For the quarter ending Q3 2025, Debt Ratio rose 2247.35% year-over-year to 0.29; the trailing twelve-month figure through Sep 2025 stood at 0.29 (up 2247.35% YoY), and the FY2024 full-year result was 0.02, changed N/A from the prior year.
- Debt Ratio for Q3 2025 stood at 0.29, up from 0.03 in the prior quarter.
- The five-year high for Debt Ratio was 0.29 in Q3 2025, with the low at 0.01 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.29 |
| Mar 31, 2025 | 0.03 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.01 |